Health Care

Rite Aid Corporation (NYSE: RAD) and drug supplier McKesson Corp (NYSE: MCK) have reached a settlement, securing the continued fulfillment of customer prescriptions throughout Rite Aid's ongoing bankruptcy proceedings.  The lawsuit against McKesson alleged that the...

Activist hedge fund Starboard Value holds a stake of around 8.7% in contract-research organization Fortrea Holdings Inc. (NASDAQ: FTRE), according to an exchange filing. The activist investor plans to push for changes that could boost margins among other initiatives...

Piper Sandler analyst Harsh V. Kumar reiterated the Overweight rating on Wolfspeed, Inc. (NYSE: WOLF), lowering the price target to $55 from $75. The company will publish its Q1 results on Monday, October 30, 2023. Given the sale of the RF business to MACOM Technology...

Blood tests for diagnosing Alzheimer's disease are eagerly awaited, but it may be a couple of years before they become a routine diagnostic tool. While several blood tests for Alzheimer's diagnosis are in development, none are approved by regulators or insurance reimbursement.  Some...

Neurocrine Biosciences Inc (NASDAQ: NBIX) released topline data from the Phase 3 CAHtalyst Pediatric Study of crinecerfont in children and adolescents with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency.  CAH is an inherited condition that affects...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) entered into a merger agreement under which its subsidiary, Pelican Technology Holdings Inc, has become a wholly owned subsidiary of Primrose Bio Inc.  Primrose Bio is a stand-alone private company focused on synthetic biology....

Needham cut the price target for Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) from $60 to $53. Needham analyst Gil Blum maintained a Buy rating. Rocket Pharmaceuticals shares rose 24.3% to $19.00 in pre-market trading. Goldman Sachs slashed Ultrapar Participações S.A. (NYSE: UGP)...

Neurocrine Biosciences Inc (NASDAQ: NBIX) announced positive topline data from the Phase 3 CAHtalyst Adult Study evaluating crinecerfont in adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD). CAH is a group of genetic conditions limiting...

The Nasdaq 100 closed higher by over 1% on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company’s prospects or that they view the stock as being overpriced. Insider sales...

Oppenheimer has initiated coverage on LeMaitre Vascular Inc (NASDAQ: LMAT) with an Outperform rating and a price target of $70. Analysts Suraj Kalia and Shaymus Contorno note that approximately 90% of current sales are generated from ~1/3rd of its core markets, including ePTFE...

Gainers Acer Therapeutics Inc. (NASDAQ: ACER) shares jumped 145% to $1.4850 after Zevra Therapeutics announced it will acquire the company. The transaction will have a total potential value for Acer stockholders of up to $91 million. 1847 Holdings LLC (NASDAQ: EFSH) surged 66.6% to $0.17. 1847...

Benchmark analyst David Williams upgraded MACOM Technology Solutions Holdings Inc. (NASDAQ: MTSI) to Buy from Hold, with a price target of $92. The analyst is bullish on MTSI acquiring radio frequency business from Wolfspeed Inc (NYSE: WOLF) for $125 million. The...

The FDA approved Neurocrine Biosciences Inc's (NASDAQ: NBIX) Ingrezza (valbenazine) capsules for the treatment of adults with chorea associated with Huntington's disease (HD). Ingrezza is the only selective vesicular monoamine transporter 2 (VMAT2) inhibitor that offers an...

The healthcare technology company Cue Health Inc. (NASDAQ: HLTH) has become the first company to get De Novo authorization from the U.S. Food and Drug Administration (FDA) for an over-the-counter COVID-19 test — as well as being the first FDA De Novo authorization for any over-the-counter...

Needham raised the price target for CyberArk Software Ltd. (NASDAQ: CYBR) from $185 to $190. Needham analyst Alex Henderson maintained a Buy rating. CyberArk Software shares fell 0.3% to $161.50 in pre-market trading. Stephens & Co. increased Carrols Restaurant Group, Inc. (NASDAQ: TAST)...